Abstract | Investigators have made key advances in rheumatoid arthritis (RA) genetics in the past 10 years. Although genetic studies have had limited influence on clinical practice and drug discovery, they are currently generating testable hypotheses to explain disease pathogenesis. Firstly, we review here the major advances in identifying RA genetic susceptibility markers both within and outside of the MHC. Understanding how genetic variants translate into pathogenic mechanisms and ultimately into phenotypes remains a mystery for most of the polymorphisms that confer susceptibility to RA, but functional data are emerging. Interplay between environmental and genetic factors is poorly understood and in need of further investigation. Secondly, we review current knowledge of the role of epigenetics in RA susceptibility. Differences in the epigenome could represent one of the ways in which environmental exposures translate into phenotypic outcomes. The best understood epigenetic phenomena include post-translational histone modifications and DNA methylation events, both of which have critical roles in gene regulation. Epigenetic studies in RA represent a new area of research with the potential to answer unsolved questions.
Introduction
Genetic and epigenetic underpinnings of RA That genetic and environmental factors participate in mechanisms of rheumatoid arthritis (RA) pathogenesis 1 is well established. The overall contribution of genetic factors to RA development has historically been investi gated through analysis of family pedigrees. For example, familial clustering-greater disease occurrence in rela tives of probands than of healthy controls-has been a consistent observation in RA; 2 the relative risk of RA development in first degree relatives of affected indivi duals is estimated at ~2 or greater. [3] [4] [5] In addition, disease discordance in monozygotic compared with dizygotic twins suggests that the genetic contribution to RA, or disease heritability, approaches 65%; 6 these estimates are, however, based on a relatively small number of twins (23 monozygotic and 10 dizygotic diseaseconcordant twin pairs). Heritability is the proportion of pheno typic variance that can be attributed to genetic, rather than environmental, causes. Thus, although RA clearly has a considerable genetic component, and few known environ mental triggers (such as cigarette smoke), 7 many environmental factors remain largely unknown and their contribution to RA aetiology is likely substantial.
Mechanisms that underlie the observed sexbias (3:1 female to male ratio) in the incidence of RA are also unknown. Investigators have suggested a range of hypotheses including potential roles for sex hormones. 8, 9 The sex chromosomes have been underinvestigated in genetic studies in RA. An Immunochip study published in 2012, 10 described in the 'Immunochip' subsection of this manuscript, shows for the first time an association with an X chromosome locus in RA, in this case IRAK1 (encoding interleukin1 receptorassociated kinase 1). This locus has been shown to escape Xinactivation in humans, 11 pointing to a possible epigenetic mechanism underlying the sex bias in RA.
Implicating the MHC
In 1969, researchers noticed that peripheral blood lympho cytes from patients with RA were nonreactive in socalled mixed lymphocyte cultures to cells of the same type from other patients with RA. 12 Investigators demon strated in 1976 that patients with RA tend to share the same HLA genes, 13 thus explaining the lack of reactivity in mixed cultures. Serotyping experiments subsequently identified an increased proportion of patients with RA who were positive for the HLA allele HLA-DRw4, in comparison with healthy controls, 14 establishing the HLA region as a genetic contributor to RA susceptibility. A decade later, further characterization of the HLA locus identified multiple RA risk alleles within HLA-DRB1, and showed that the molecules they encoded shared a conserved amino acid sequence; this finding led to the 'shared epitope' hypothesis. 15 HLA molecules that contain this 5aminoacid sequence, which is encoded by shared epitope alleles and is arranged around the anti genbinding groove, are associated with the develop ment of anticitrullinated protein antibodies (ACPA), and -mostly-with ACPApositive RA. Although this feature is thought to influence the affinity of binding to citrullinated peptides, and to modulate Tcell responses, the precise biological implications of the shared epitope are not yet clear; 1 as we discuss in this manuscript, new associations with ACPAnegative RA complicate the shared epitope theory.
Non-MHC associations with RA Outside of the MHC region, candidate gene studies performed prior to 2007 had identified only a handful of RA susceptibility loci, including PTPN22 (encoding tyrosineprotein phosphatase nonreceptor type 22), 16 proteinarginine deiminase type 4 (PADI4) 17 and cyto toxic Tlymphocyte protein 4 (CTLA-4) 18 By 2007, genomewide association studies (GWAS) had become possible due to several major preceding advances, includ ing the completion of the Human Genome Project in 2001 19 and the initial release of the International HapMap project data in 2003. 20 These initiatives enabled the design of singlenucleotide polymorphism (SNP) chips with good coverage of variations that occur across the entire genome. In the past 5 years, these technologies have escalated the rate of discovery of diseaseassociated vari ants, and around 60 risk loci for RA are now known in European and Asian populations. 10, 21, 22 This advance has been aided by the attainment of large, well characterized, and homogeneous (that is, ACPApositive) collections of samples from patients.
GWAS power and undiscovered associations
By design, GWAS are powered to detect associations with variants that are common in the population (minor allele frequency >5%). Most of the variants identified to date in GWAS in RA, and in other complex diseases, have modest effect sizes, with odds ratios of 1.5 or less. 22, 23 These associations are potentially caused by causal vari ants that are in tight linkage dis equilibrium with the observed variants. Given that their effect sizes are so modest, each of these alleles individually explains a small fraction of the genetic contribution to RA susceptibility. Currently, all RA genetic risk factors taken together only explain ~16% of the total sus ceptibility (heritable and environmental). 22, 24, 25 Hundreds of common risk alleles are likely to exist but remain undiscovered to date owing to the limited power of current GWAS. A recent analysis by our group suggests that hundreds of uncharacterized Key points ■ Nearly 60 loci associated with susceptibility to rheumatoid arthritis (RA) have been identified across multiple populations, and are at least partially shared between ethnicities ■ Five amino acid positions, all located in peptide-binding grooves, almost completely explain the association between MHC polymorphisms and RA risk, revitalizing the 'arthritogenic peptide hypothesis' ■ Cumulatively, genetic markers identified to date explain only 50% of RA heritability ■ Using genetics to identify causative disease pathways represents a major challenge for the future ■ Epigenetic changes in RA remain underexplored and represent a promising new area to link genetics and gene expression with disease risk ■ Although genetics can be used to stratify disease risk, clinical predictions for the development and progression of RA cannot yet be performed with sufficient accuracy in individual patients SNP associations throughout the genome, taken together with known risk alleles, in aggregate explain ~36% of RA disease risk. 25 SNP associations and known risk alleles therefore account for only about half of the esti mated 65% of RA risk that is thought to be heritable. Sequencing experiments in the coming years have the potential to identify causal variants across the entire allele frequency range, including low frequency variants.
Better genotyping-accurate phenotyping Of prime importance for future genetic studies is strati fication of samples by distinct phenotypic subgroups of RA. Although the clinical presentation at disease initia tion is very similar between patients with ACPApositive and ACPAnegative RA, disease course, possibly disease pathogenesis, 26 and genetic susceptibility 27, 28 are differ ent. The association of RA with the shared epitope is, as we have mentioned, different between the two serotype subsets. 27 Now, it further seems that nonHLA SNPs asso ciated with RA susceptibility are only partially shared between ACPApositive and ACPAnegative patients with RA, 28 confirming the hypothesis that ACPApositive and ACPAnegative RA are two genetically different diseases. 29 Although patients with ACPAnegative RA included in genetic studies satisfy the 1987 American College of Rheumatology classification criteria for RA, 30 concerns remain about mis classification in this subgroup of patients. 26, 29 Nevertheless, even if ACPAnegative RA represents a heterogeneous disease group, the overall contribution of genetic factors to disease susceptibility in ACPAnegative RA seems to be as high as for ACPA positive RA. 31 Interestingly, we could show that the pattern of association of ACPApositive susceptibility SNPs with ACPAnegative RA (in terms of effect size or pres ence or absence of an association) cannot be explained solely by contamination with erroneously characterized ACPApositive samples, because the ratios of the effect sizes between ACPApositive and ACPAnegative RA vary widely for different genetic markers. 28 Nevertheless, ACPAnegative RA is likely to be subclassified in the future on the basis of further types of autoantibody. In 2011, antibodies against carbamylated proteins (antiCarP anti bodies) were shown to be present in around 20% of patients with ACPAnegative RA. 32 Furthermore, anti CarP antibodies were associated with more severe joint damage in this group. 32 Twin studies have also estab lished important differences between ACPApositive and ACPAnegative disease. 31 Although heritability esti mates remain similar in both serological strata, the con tribution of the HLA-DRB1 shared epitope alleles differs markedly, explaining 18% and 2.4% of RA heritability in ACPApositive and ACPAnegative patients, respectively. 31 Functional implications of risk alleles One of the biggest challenges for the future will be to elucidate the biological mechanisms in which risk alleles operate. We are already beginning to understand which cells are central to RA pathogenesis. For example, CD4 + effector memory T cells specifically express many of the genes located within RAassociated loci. 33 Also, certain 36 (in addition to CD28) 37 poly morphisms are associated with RA risk. Nevertheless, the translation of genetic findings into clinical applica tions is often more challenging than originally postu lated. 38, 39 As we discuss in detail below, an association study published in 2012 35 examining the entire MHC region could not confirm the frequentlyreported associ ation of TNF polymorphisms with disease susceptibility, although antiTNF treatment has substantially improved quality of life for patients with RA.
MHC genes and risk of RA
The early days and unresolved hypotheses The discovery of a strong association between HLA-DRB1 and RA was initially made using antibodies to specific MHC class II proteins and thus serotyping indivi duals according to the surface expression of anti genic molecules on their circulating B cells. Stastny 13, 14 found that substantially more patients with RA were positive for the Bcell alloantigen DRw4 (later renamed DR4) than were healthy individuals. Subsequently, investigators used cloning and sequencing experiments to characterize different alleles at that gene locus (now called HLA-DRB1). According to the current nomen clature, 39 HLA-DRB1*04 denominates the allele group corresponding roughly to the archaic serotypic classifi cation DRw4, while the next appendant digit set defines a specific allele; for example, HLA-DRB1*0401. A decade after Stastny's discoveries, Gregersen et al. 15 showed that molecules encoded by RAassociated HLA-DRB1 alleles share a common amino acid sequence in the third hyper variable region of the DRβ1 chain-the shared epitope. A Tcell epitope is, by definition, a threedimensional structure recognized by a paratope (the Tcell receptor [TCR] ) and constituted in part by the MHC molecule and in part by the antigenic peptide bound in the groove. The term 'shared epitope' , therefore, suggests the exist ence of an autoantigenic peptide that has not unequivo cally been identified after two decades of research. As a result, the 'arthritogenic peptide hypo thesis' 15, 40, 41 remains controversial 42 and, although shared epitope alleles are established genetic risk factors in RA, the immunological implications of their expression remain uncertain. RA demonstrated strong and significant linkage of the disease with the MHC region, but not consist ently with any other region in the genome. [43] [44] [45] [46] [47] As we have mentioned, linkage with the MHC applied only to ACPApositive, not ACPAnegative, RA. 27 Initially, MHC associations with ACPApositive RA were attrib uted to HLA genes; however, shared epitope alleles at the HLA-DRB1 locus do not fully explain the associa tion of the MHC region with RA-several studies in which the HLA-DRB1 effect was controlled for have suggested additional independent associations within the MHC. [48] [49] [50] Until 2012, MHC alleles were thought to be exclu sively associated with ACPApositive RA. Now, several reports from wellpowered studies have identified and confirmed the association of the shared epitope with ACPAnegative RA. 10, 28, 51 The role of this association and its possible restriction to specific serotypes or subtypes of ACPAnegative RA remain to be determined.
Revisiting the shared epitope hypothesis
Despite advances in highthroughput SNP genotyping technologies, the application of probebased genotyping to query HLA genes within the MHC has been limited, owing to the highly polymorphic nature of these genes. Historically, investigation of HLA genes required direct PCRbased genotyping. Twentyfirst century advances in statistical genetics have now facilitated imputation of HLA alleles based on SNP data. 52, 53 Imputation employs a large reference data set from individuals genotyped for classical HLA alleles and HLA SNPs to determine the most likely HLA alleles in individuals for whom SNP data over the HLA region, but not direct HLA g enotyping, are available.
In 2012, we applied this imputation approach to SNP data from the 2010 GWAS metaanalysis by Stahl et al. 22 ( Figure 1 ), and demonstrated that the risk of RA associ ated with the HLA-DRB1 gene correlates most strongly with the amino acid residue in position 11, located at the bottom of the DRβ1 antigenbinding groove. 38 Amino acids 71 and 74, whose sidechains constitute the surface of the antigenbinding groove, also correlated indepen dently with susceptibility to RA. In addition, we found independent RA risk alleles in HLA-B and HLA-DPB1; in both cases, signals from these regions were best explained by a variation in a single amino acid site at the bottom of their respective antigenbinding grooves. No further signal of an association with RA was found within the MHC when we controlled for the independent effects mentioned here. That is, these genetic variants in HLA-B, HLA-DRB1 and HLA-DPB1-affecting a total of 5 amino acid positions-almost completely explained the variance in RA risk caused by the MHC region. Although other SNP associations are indeed possible within the MHC and other HLA genes, such variants are likely to have comparatively weak effects in conferring susceptibility to RA. Importantly, no association signal with RA was identified within the TNF region, indicat ing that frequently reported associations between TNF promoter polymorphisms and RA susceptibility were probably confounded by nearby HLA-B, HLA-DRB1 and HLA-DPB1 gene variants.
Interestingly, when haplotypes of alleles for the 3 RAassociated amino acid positions within the locus were studied and coded using the classical 4digit HLA-DRB1 allele nomenclature, the hierarchy of HLA alleles associ ated with risk of, and protection from, RA was consist ent with previous classification systems or studies: 51, [54] [55] [56] [57] [58] [59] [60] for example, shared epitope alleles were associated with greatest susceptibility to RA, whereas HLA-DRB1*1301 54 was part of the most protective haplotype (Table 1) . 38 A large European metaanalysis in 2010 confirmed HLA-DRB1*1301 as a protective allele for RA. 54 Linking HLA alleles to function The finemapping of MHC polymorphisms that we describe above confirms that HLADRB1 modulates sus ceptibility to RA, and defines a few amino acids, includ ing positions 71 and 74 originally highlighted in the shared epitope hypothesis, as determining the effect. 38 Further, the data extend associations with RA to HLAB and HLADPB1. Most interestingly in biological terms, sidechains of amino acids in the positions that alter sus ceptibility to RA all point towards the peptidebinding groove, revitalizing the 'arthritogenic peptide hypothesis' . Lack of identification of an 'RA antigen' to date might, therefore, be related more to technical challenges than to its non existence. Indeed, the wellestablished effectsize hierarchy of classical shared epitope alleles (Table 1 and  reviewed elsewhere) 51,55 might correlate with the HLA binding affinity of an antigenic peptide 61 and, ultimately, with its immunogenicity. 62, 63 The next step in character izing this potential pathogenic mechanism consists of identifying Tcell autoantigens in ACPApositive RA. New structural information regarding the peptide binding groove 38 and the importance of citrullination with regard to binding affinity will help in the selection of peptides from putative target proteins for reverse en gineering experiments. 64 
Non-HLA SNPs
High-throughput SNP genotyping Since 2000, highthroughput SNP genotyping has success fully facilitated case-control association studies in RA to test putative links with genetic variants outside the MHC. 24, [65] [66] [67] In 2003, Suzuki et al. 68 identified a SNP in the third intron of PADI4 that contributed to the risk of RA in Japanese populations (Figure 2) . A year later, Begovich et al. 16 identified a nonsynonymous SNP in PTPN22 as a risk variant in white individuals in the USA; this variant remains the most strongly RAassociated SNP identified to date with an odds ratio of 1.8 for ACPApositive RA. Subsequent case-control studies investigating other can didate gene associations have suggested only a handful of additional susceptibility loci (among them CTLA-4,
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TRAF1
69 and FCRL3
70
); most loci identified in c andidate gene studies were not reproducible in independent studies. 18 In 2007, investigators in RA genetics published three separate GWAS in RA, [71] [72] [73] including one within the multidisease Wellcome Trust Case-Control Consortium study. 73 Several of the many new RA susceptibility SNPs (reviewed elsewhere) 37 identified in these GWAS [71] [72] [73] and subsequent studies are described in this section. GWAS have now been used to identify risk factors for RA in populations of European and Asian descent. 21, 22, [68] [69] [70] [71] [74] [75] [76] [77] Meta-analyses of data from GWAS Imputation techniques, which have become standard tools to determine the genotype of ungenotyped SNPs, 78 facilitate powerful metaanalyses of GWAS data origi nating from different genotyping platforms. Two large RA GWAS metaanalyses have independently exam ined different populations: Stahl et al. 22 analysed data from people of European descent in 2010 (initially 5,539 patients with ACPApositive RA and 20,169 controls, replicated using data from a further 6,768 patients and 8,806 controls), whereas Okada et al. 21 used data from Japanese individuals (initially 4,074 with RA and 16,891 controls, then a further 5,277 patients and 21,684 con trols) in 2012-these analyses identified 7 and 9 novel RA risk alleles, respectively.
Another approach to investigating the genetic basis of susceptibility to RA is to examine shared genetic bases between it and other autoimmune diseases, or across dif ferent ethnicities; genes, including ubiquitinconjugating enzyme E2 L3 (UBE2L3) 79 , DEAD (AspGluAlaAsp) box helicase 6 (DDX6; encoding probable ATPdependent RNA helicase DDX6) 80 , and IKAROS family zinc finger 3 (Aiolos) (IKZF3, encoding zinc finger protein Aiolos), 81 have been thus implicated. Okada et al. 21 conducted a multiancestry comparative analysis of 46 risk loci between the Japanese data we have mentioned and data from individuals of European descent-5,539 patients with RA and 20,169 controls. Six of these sites were monomorphic in Japanese people (that is, all Japanese individuals have the same genotype at that locus), but all were polymorphic in individuals of European des cent. Significant associations with RA (false discovery rate <0.05, P <0.0030) were found at 22 loci in Japanese people and at 36 loci in those of European descent; 14 of these signals were shared. Indeed, a comparison of all tested SNPs across the two populations showed a posi tive correlation of odds ratios for of a large proportion of SNPs between cohorts of indivi duals of European descent and Japanese cohorts, indicating shared genetic suscepti bility alleles. 21 Ethnogenetic hetero geneity in RA has been reviewed previously in this journal. 82 Of note, the focus of metaanalyses to date has been almost exclusively on ACPApositive RA. Genetic architecture differs between ACPApositive and ACPA negative RA, 48 and RA susceptibility loci are only partial ly shared between the two serotypes.
10,28
Immunochip Immunochip, a custom SNP array, facilitates dense geno typing and finemapping at 186 genetic loci, includ ing confirmed autoimmune loci and other alleles with nominal GWASbased evidence of an association with an autoimmune disease. Collaborating with investiga tors worldwide, our group genotyped 11,475 patients of European descent with RA and 15,870 controls at 130,000 markers using Immunochip, identifying 14 novel RA risk loci. 10 Furthermore, we refined to single genes the association signals of 19 previously identified loci. Secondary independent effects (defined as a remaining association at P <5 × 10 −4 after conditioning on the most associated SNP of the region) were identified at 6 loci, and nonsynonymous exonic SNPs or SNPs located within an essential splice site suggested putative causality at 7 loci. Interestingly, PADI4 polymorphisms, unequivo cally associated with RA in Asian populations in previ ous studies, were significantly associated (genomewide; P <5 × 10 −8 ) with RA in patients of European descent in this study. 10 Although a PADI4 variant was historically the first RAassociated polymorphism to be identified outside the HLA, its association has been controversial in populations of European descent.
Aetiopathogenetic mechanisms
Connecting genotype to phenotype in RA Few genetic markers of RA susceptibility have been experimentally linked to functions, and many different molecular mechanisms are implicated. Indeed, the first molecular steps by which a SNP influences phenotype might involve alterations in transcriptional activity, epi genetic modifications, microRNA regulation, splicing, mRNA or protein stability, translation, protein activ ity or posttranslational modifications. In this section, we review RA susceptibility loci for which roles have been investigated experimentally after their discovery in GWAS.
PTPN22
The most studied polymorphism in RA to date is the PTPN22 nonsynonymous Arg620Trp SNP rs2476601. Tyrosineprotein phosphatase nonreceptor type 22 (known as PTPN22 and encoded by PTPN22), down regulates TCR signalling by dephosphorylating Src family kinases, such as Lck or Fyn (Figure 3) . Although evidence indicates that the PTPN22 risk allele affects the enzymatic activity of the encoded phosphatase, 83 the influence of the Arg620Trp variant on the immune response has been controversial-in 2005, a gainof function consequence was reported, 84 but further func tional studies have been inconsistent. In 2011, Zhang et al. 85 showed that rs2476601 is a lossoffunction allele that mediates its effect by destabilizing PTPN22 (or its mouse homolog). The variant phosphatase is targeted for degradation both by calpain proteases and through ubiquitinmediated proteasomal degradation. Reduced levels of the protein correlate with increased number, activation and thymic positive selection of T cells, and with dendriticcell and Bcell activation. In 2012, the function of PTPN22 was linked to the thymic develop ment of regulatory T cells, 86, 87 and alternative molecu lar mechanisms as heterogeneous as imbalance in the expression of PTPN22 splice variants 88 and differential allelic expression 89 have been suggested.
PADI4
PADI4 mediates posttranslational conversion of argi nine residues to citrulline. Originally, 68 an RA suscep tibility haplotype was shown to increase the stability of PADI4 mRNA transcripts and was associated with ACPA positivity in patients with RA. Citrullinated pep tides bind with higher affinity to HLADRβ1 shared epitope molecules, 61, 90 are naturally processed, 91 and are immuno genic. 62 Thus, it seems that increased translation of variant PADI4 mRNA boosts production of citrulli nated peptides, which act as autoantigens and elicit pro found adaptive immune responses. Whereas many other risk loci seem to be connected to multiple autoimmune diseases, the PADI4 locus is specific to RA. Inferring function from data outside RA Other than PTPN22, PADI4 and CCR6, few other risk loci have been investigated functionally in RA. Nevertheless, knowledge has been gained from studies in healthy in dividuals or in the context of other a uto immune diseases.
IL2RA
Autoimmunityassociated SNPs located in noncoding genomic regions in the vicinity of IL2RA (encoding IL2 receptor subunit α) have been shown to correlate with IL2RA mRNA and surface protein expression levels in monocytes, CD4 + naive T cells and memory T cells, but not in other cell types tested. 94 According to the quantal theory of immunity, Tcell responses depend on a criti cal number of stimuli mediated by TCR and IL2R, 95 which could explain different activation thresholds in the Tcell compartment of individuals polymorphic at the IL2RA locus.
TNFAIP3
TNFAIP3 encodes TNFinduced protein 3 (TNFAIP3), a ubiquitinmodifying enzyme that is a key regulator of nuclear factor κB activity (Figure 3 ). Three SNPs within the TNFAIP3 locus are independently associated with RA susceptibility. 96 In patients with systemic lupus ery thematosus (SLE), a polymorphism located in a highly conserved region of TNFAIP3 has been shown to reduce mRNA and protein expression of the gene, seemingly by reducing the avidity with which a nuclear protein complex of NFκB subunits binds to it. 97 Indicating the importance of celltype specific expression, mice with conditional knockout of Tnfaip3 expression in dendritic cells develop an SLElike phenotype, 98 whereas mice lacking Tnfaip3 in myeloid cells develop an RAlike phenotype. 99 
Bioinformatic analysis approaches
A biologically pragmatic way to define a pathway is to consider it as a chronological succession of molecular Odds ratios 10, 21, 22, 79, 80 for RA genetic susceptibility loci are presented in the approximate chronological order of discovery (blue and orange bars). Only susceptibility loci in white cohorts (blue) were included in calculating the proportion of phenotypic variance explained. Loci validated only in east-Asian populations are shown in orange; although the loci identified by Okada et al. 21 were published a few months before the Immunochip study, 10 they are presented at the far right of the plot for graphical convenience. Shared loci across different populations are shown at the time of their discovery in white cohorts. A 0.5% disease prevalence was assumed for calculations. For simplification, every locus is represented once, even if multiple independent effects were identified (except for TNFAIP3). The cumulative percent variance explained by the loci is indicated by the red line. Abbreviation: RA, rheumatoid arthritis.
interactions occurring between cells or within a cell, starting with a signal (input) and ultimately resulting in a response (output). This linear definition of pathways conveniently allows experimental testing, as responses to signals can be measured. Several bioinformatic tech niques have been proposed to analyse postGWAS data as a whole and to identify RAspecific mechanisms of disease progression. 98 In this section, we describe how bioinformatic techniques, such as pathways and net works analyses and integrative systematic approaches, are applied to functional analysis of putative RA risk alleles. Importantly, bioinformatic definitions of path ways are often nonlinear and do not lend themsleves to experimental validation; an important challenge for the future will be how to biologically validate integrated bioinformatic analysis approaches.
Representing the TCR intracellular signalling pathway as a schematic linear series of molecular events provides an example of how RA susceptibility loci can be matched with potential roles in a biological model of pathology, and yet also illustrates how complex such efforts are. Indeed, many of the known loci associated with RA are involved in the TCR signalling pathway, but intricate interactions link these components with other signalling pathways in even a simplified depiction (Figure 3) . Thus, although plausible functional explanations for how genetic variants confer RA risk can be generated, it remains to be experimen tally demonstrated that RA risk alleles in aggregate alter, for example, the efficiency of TCR engagement (input), subsequent signal transduction events, and consequent production of IL2 (output).
Pathway analysis
The generic term 'pathway analysis' is loosely defined in the literature and has been used to refer broadly to systematic analyses examining sets of genes for common functional properties. In some instances, this broad defi nition, instead of a clear linear one, can be misleading; for example, the 'cellular compartment' ontology (or pathway) in the Gene Ontology (GO) classification does not describe a biological pathway, rather it describes the specific cellular locations where a protein localizes. 99 
Database-driven pathway analysis
Several studies have analysed GWAS data for enrichment in genes belonging to specific biological pathways, as defined by pathway classification tools such as GO, Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, PantherDB and BioCarta. [100] [101] [102] [103] Biological notions of path ways, as well as detail and quality of annotation, differ between pathway databases. [104] [105] [106] As a result, outcomes of databasedriven pathway analyses depend on the pathway ontologies used. 107 Nevertheless, such analyses have con firmed broad statements about the aetiology of RA by showing enrichment of RA susceptibility loci in pathways related to immune functions, 100, 101 Tcell activation and/or differentiation, 101, 102 JAKSTAT pathway signalling, 102 and Figure 3 | Mapping of 11 RA susceptibility loci to pathways involved in the 'T-cell-dendritic-cell dialogue'. The gene products (blue) of several RA susceptibility loci are implicated in the three pathways represented here-the TCR, TNF and CD40 signalling pathways. To avoid overloading the picture and to represent pathways as linear and chronological successions of molecular interactions, several membrane-associated factors are schematically represented in the cytosol and many key molecules or interactions have been omitted (for example, the p38 and JNK pathways, CD28 co-stimulation, and adhesion mediated by CD2 and CD58). NFκB is a homodimer or heterodimer containing 2 of the following subunits: RelA, RelB, c-Rel, NFκB1, NFκB2. Only c-Rel is associated with RA. CD45 and PKC-θ are encoded by PTPRC and PRKCQ respectively; both of these genes are within RA susceptibility loci. Abbreviations: NFκB, nuclear factor κB; PTPN22, tyrosine-protein phosphatase nonreceptor type 22; TCR, T-cell receptor; TNFR1: TNF receptor 1; TNFAIP3, TNF-induced protein 3.
▶ FOCUS ON RATIONAL THERAPY IN RA
TNF signalling. 101 Novel approaches are required to gain a more differentiated picture of causal molecular events.
Network analysis
Another way to investigate the function of RA suscepti bility loci in biological pathways is through bioinformatic identification of proteins that their products physically interact with. Such approaches commonly include protein-protein interaction network analyses. Proteinprotein interaction databases such as the Human Protein Reference Database 108 or text mining techniques such as GRAIL 35 can be used to construct networks. Other emerging techniques integrate pathway and network oriented analysis. 109, 110 Several proteins encoded by RA susceptibility genes are consequently thought to interact or bind with each other (Figure 4 ).
108,109
Inferring pathways from expression data Cellspecific expression analysis can, as a proxy for gene function, be particularly useful in identifying pathways, cell types, and regulatory programmes relevant to RA. Our group recently mapped RA susceptibility markers to specific cell types. 33 As a comprehensive and unbiased catalogue of gene functions is not available, we used a compendium of gene expression data as an objective proxy for tissuespecific gene function. We observed that CD4 + effector memory T cells were highly enriched for the specific expression of genes within RA risk loci. Integrating data-the SLE example A 2012 systematic review of putative pathogenic mecha nisms in SLE illustrates how experimental data from various sources can be integrated into a single disease model: SLE pathology is hypothesized to result from type I interferon (IFN) misregulation. 111 Data from singlegene disorders, GWAS, gene expression micro arrays, and serologic studies tend to converge towards a linear disease model: immune complexes bind to Toll like receptors (TLRs) on plasmacytoid dendritic cells; type I IFN production by dendritic cells is triggered; IFN binds to its receptor on target cells; JAKSTAT signalling is activated and the expression of hundreds of genes-the 'IFN signature'-is altered, leading to disease manifes tation. Type I IFN levels and its signature can both be directly measured in peripheral blood. Of 47 loci asso ciated with SLE susceptibility, 27 (57%) are involved in type I IFN production or signalling. Evidence supporting the direct involvement of type I IFN in SLE pathogenesis has paved the way for new therapeutic approaches tar geting type I IFN. 111 No such evidence of a clear disease pathway is available yet for RA.
Epigenetics of RA
Results from twin studies support a substantial role for environmental triggers in determining RA risk, as evi denced by high discordance rates between monozygotic twins. 6 However, the identities of nonshared environ mental exposures remain largely elusive. One of the ways in which individuals may respond to an environ mental exposure is through changes in their epigenome. The bestunderstood epigenetic phe nomena include posttranslational histone modifications and DNA methylation, both of which have a profound influence on gene expression. 112 
Epigenetic mechanisms
Methylation of DNA cytosine residues at the carbon 5 position, generating 5methylcytosine, occurs pri marily in the context of cytosineguanine dinucleotides (CpGs). An unexpected feature of the human genome is the rela tive paucity of CpGs due to the frequent mutation of 5methylcytosine to thymine. 113 Regions of the genome with high CpG content, termed CpG islands (CGI), 114 are often hypomethylated and are associated with the promoter regions of actively transcribed genes. 115 Methylation in regions up to 2kb away from CGIs (termed GpG island shores) can also strongly influence gene expression. 116 Nterminal tails of histone proteins are subject to a wide range of different modifications including acetyla tion, methylation, phosphorylation and ubiquitylation. More than 60 different histone modification sites have been described. 117 A mechanistic connection clearly exists between histone modifications and DNA methyla tion. 118 For example, the presence of DNA methylation reportedly promotes deacetylation of histone 4 and dimethylation of histone 3 at lysine 9, as well as inhibit ing methylation of histone 3 at lysine 4, all of which are important modifications that inhibit gene repression. 119 
Environmental influences
The epigenome has sufficient plasticity to react to the internal and external environment; a range of environ mental exposures (such as xenobiotic chemicals and behavioural cues) 120 can alter the epigenome. For example, DNA methylation levels at the F2RL3 locus (the gene for proteinaseactivated receptor 4) are sig nificantly lower in individuals exposed to cigarette smoke. 121 In a related study, F2RL3 methylation status was reported to mediate smokingassociated mortality in patients with stable coronary heart disease. 122 Induced epigenetic changes can be inherited during cell division, thereby maintaining the acquired phenotype in daugh ter cells. 120 In addition, stochastic epigenetic instability may accumulate over time in multiple cell types in the absence of obvious environmental stimuli. For example, methylation patterns are more poorly conserved than DNA sequences during mitosis. The error rate for the maintenance of methylation is approximately 10 -3 per base pair, whereas the error rate for DNA sequence is approximately 10 -6 per base pair. 123 Phenotypic differ ences in genetically identical siblings could conceiv ably be determined more by this stochastic variation in the epigenome than by epigenetic differences due to nonshared environmental effects. 124 
Cell-type considerations
The pluripotency of cells decreases during cellular dif ferentiation as gene expression programmes become more restricted. 125 This process, which results in the acquisition of celltype specific features, is controlled epigenetically and is characterized by a specific set of histone modifications and DNA methylation patterns. For example, histone acetylation at the IFNγ promoter occurs during differentiation of naive T helper (T H 0) cells into cells with the T H 1 phenotype. 126 This modifi cation reduces the affinity between the histone and DNA, increasing access for transcription factors. When inves tigating epigenetic alterations in the context of disease pathogenesis it is therefore essential to focus on a pure or enriched cell type that is relevant to the disease under investigation. This requirement is particularly challeng ing in RA, wherein the most relevant cell subsets are not immediately obvious.
Epigenetic studies in RA Data for epigenetic phenomena in RA are currently limited, especially in terms of study scale and power. 127 However, some interesting observations from studies of DNA methylation patterns are beginning to emerge. For example, analysis of DNA methylation in T cells has revealed global hypomethylation in cells derived from patients with RA compared with those from healthy con trols. 128 DNA hypomethylation has also been observed in RA fibroblastlike synoviocytes (FLS), as compared with normal FLS, derived from small joint posttrauma biopsy samples. 129 In 2013, Nakano et al. 130 published a genome wide evaluation of FLS derived from patients with RA or osteoarthritis (OA), reporting that as many as 1,859 loci, relevant to cell movement, adhesion and trafficking, were differentially methylated in RA (732 hypo methylated and 1,127 hypermethylated). This study was performed using the latest Illumina HumanMethylation450 BeadChip, which provides comprehensive gene region (for exam ple, promoter, exon 1, gene body, 5' and 3' untrans lated regions) coverage of over 96% of NCBI Reference Sequence genes.
In a genetargeted approach Nile et al. 131 investigated DNA methylation patterns in the promoter region of IL6 in peripheral blood mononuclear cells (PBMC) derived from patients with RA (n = 8) and healthy controls (n = 5). This study identified a single CpG motif 1,099 base pairs upstream of the IL6 transcription start site that was less methylated in patients with RA than in controls. Electrophoretic mobilityshift assay (EMSA) experi ments supported this finding in that reduced methyla tion at the -1,099 locus was reported to correlate with increased binding of nuclear proteins to the genomic DNA. 131 However, further experiments in isolated B cells will be needed to further support these interesting data.
Representing a new class of modulators of gene expression, miRNAs basepair with the 3'untranslated region of target mRNAs leading to mRNA degradation or inhibition of translation. 132 Increased expression of miRNA115 133 and miRNA203 134 has been observed in RA FLS (compared with OA FLS) and this increase corre lates with elevated levels of matrix metalloproteinase1 (MMP1) and IL6. It is important to note that expres sion of miRNA115 132 and of miRNA203 134 are inversely correlated with levels of DNA methylation.
Improving epigenetic knowledge in RA Correct study design will be critical if our understanding of the role of epigenetic alterations in RA is to expand. Retrospective case-control studies are possible and may also include GWAS information, but care must be taken to ensure that observed differences reflect true epi genetic differences and not variance in, for example, celltype composition. Retrospective studies are limited in that they cannot determine whether an observed epi genetic mark is causal or consequential (secondary, for example, to therapeutic intervention or the inflammatory response). Investigations including disease discordant monozygotic twins are useful as they control for dif ferences due to germline sequence variation and gender; however, unless samples are collected longitudinally, which would be very difficult in a late onset disease such as RA, cause will not be distinguished from consequence. Longitudinal cohorts of people initially free from disease (for example, the 1958 birth cohort in the UK) 135 would avoid confounding due to differences in recruitment of cases and controls, and avoid bias due to casecontrol dif ferences in the measurement of nongenetic risk factors. Longitudinal cohorts would be essential for establish ing the temporal origin of deleterious events and distin guishing causal from consequential effects. 136 Important considerations in designing epigenetic studies include sample throughput methods and genome coverage and resolution. For studies of DNA methylation, arraybased approaches involving bisulphite conversion are currently the most powerful, but a shift towards wholegenome bisulphite sequencing is likely in the future. 137 Epigenetic alterations might prove useful in the clini cal setting as markers of disease progression or response to treatment. Furthermore, epigenetic alterations pro vide new and important targets for the development of therapeutics in RA. Histone deacetylase inhibitors (HDACIs) are currently the beststudied epigenetic therapeutic agents. 138 The antiinflammatory properties of HDACIs include reductions in the levels of cytokines such as TNF, IL6 and INFγ. 139, 140 HDACIs could repre sent, in the future, a suitable therapeutic option for the treatment of autoimmune diseases such as RA as they are well tolerated at low doses and orally active. 141 
Future directions
Future challenges in understanding and leveraging RA genetics and epigenetics include further identifi cation of causal genetic variants and their functional characterization, investigation of the role of epigenetic modifications in RA pathogenesis, and translation of fundamental discoveries into clinical practice. Accurate risk prediction in susceptible individuals 142 will allow preventive intervention; in patients, individual predic tions of disease outcome 143 and treatment response 144 will pave the way to personalized medicine and allow more efficient patient care. A better understanding of RA molecular pathogenesis will enable the development of new in tervention strategies. Those future tasks are likely to be achieved by the use of new technologies and innovative research strate gies. Nextgeneration sequencing will facilitate whole exome and wholegenome investigations, in particular studies of the role of rare (<0.5%) genetic variants in large cohorts. Rare variants might explain a certain pro portion of the missing heritability of RA, and growing evidence indicates that such alleles are functionally important, pene trant, and harbour larger effect sizes than common variations. 145, 146 Deep resequencing, which identified new and independent effects in other autoimmune diseases, 147, 148 could be applied to RA. New technologies will also drive epigenetic studies. 137 Epigenetic modifications are potentially influenced by genetic factors as well as by environmental signals including those, such as cigarette smoke, that are known to influence RA risk.
Conclusions
Despite the large number of RA susceptibility loci identified in recent years, genetic risk prediction of RA cannot be performed with sufficient accuracy to enter clinical practice. 149, 142 Nevertheless, as a result of GWAS and related studies, new pathogenic pathways have been revealed, and mechanisms of some existing drugs are becoming clearer. Genetic sequence variants are unlikely to explain all of the variation in gene function that underpins RA. Correct gene function also depends on appropriate epigenetic programming, which differs between cell and tissue types, and between different stages of cellular development.
Little is currently known about the extent of epi genetic burden in RA; however, epigenetic data in this disease are beginning to accumulate. It will be impor tant for future epigenetic studies in RA to focus on the correct cell types and, in targeted approaches, the correct biological pathways.
Genetic testing has already entered clinical practice in oncology and predicting drug response is currently part of everyday practice in some oncologic sub specialities. Although the genetic architecture of disease suscepti bility, severity and treatment response differs signifi cantly between cancers and autoimmune diseases, genetic testing is likely to enter clinical practice in rheumatology in the next decade.
Review criteria
The PubMed database was searched using the following terms: "genetics AND (rheumatoid OR arthritis)", "epigenetics AND (rheumatoid OR arthritis)" for full papers and abstracts published online and/or in print in English up to June 2012. References to be included were selected by the authors according to their opinion of their relevance to the scope of this Review, and further papers were identified from the reference lists of relevant publications. Some reports published after June 2012 and identified during revisions to this manuscript have also been included. Pathways presented in Figure 3 were curated manually from the literature; only well established interactions were considered.
